231 Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy
D. Surguladze, M.J. Plym, J. Malaby, M. Prewett, M. Rutstein, J. Schwartz, D. Lu, L. Witte, J.R. TonraVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)71936-4
File:
PDF, 45 KB
english, 2010